J
Jennifer E. Van Eyk
Researcher at Cedars-Sinai Medical Center
Publications - 461
Citations - 25039
Jennifer E. Van Eyk is an academic researcher from Cedars-Sinai Medical Center. The author has contributed to research in topics: Medicine & Proteome. The author has an hindex of 77, co-authored 412 publications receiving 20853 citations. Previous affiliations of Jennifer E. Van Eyk include Johns Hopkins University School of Medicine & University of British Columbia.
Papers
More filters
Posted Content
New views of old proteins: clarifying the enigmatic proteome
Integrative Proteomics,Kristin E. Burnum Johnson,Thomas P. Conrads,Richard R. Drake,Amy E. Herr,Ravi Iyengar,Ryan T. Kelly,Emma Lundberg,Michael J. MacCoss,Alexandra Naba,Garry P. Nolan,Pavel A. Pevzner,Karin D. Rodland,Salvatore Sechi,Nikolai Slavov,Jeffrey M. Spraggins,Jennifer E. Van Eyk,Marc Vidal,Christine Vogel,David R. Walt,Neil L. Kelleher +20 more
TL;DR: In this article, the authors discuss grand opportunities to transition the science of proteomics into a more propulsive enterprise, and offer potential futures for a next generation of disruptive approaches to define, quantify and visualize the multiple dimensions of the proteome, thereby transforming our understanding and interactions with human disease.
Journal ArticleDOI
COT: an efficient and accurate method for detecting marker genes among many subtypes
Yingzhou Lu,Chiung-Ting Wu,Sarah J. Parker,Zuolin Cheng,Georgia Saylor,Jennifer E. Van Eyk,Guoqiang Yu,Robert Clarke,David M. Herrington,Yue Wang +9 more
TL;DR: An efficient and accurate data-driven method, formulated as a Cosine-based One-sample Test (COT) in scatter space, to detect MG among many subtypes using subtype expression profiles and demonstrates the performance and utility of COT on both simulated and real gene expression and proteomics data.
Patent
Methods of diagnosing muscle damage
TL;DR: In this article, a method for assessing muscle damage in a biological sample obtained from a subject is disclosed, which is applicable to cardiac muscle and skeletal muscle and can also be used to assess the extent and/or type of muscle damage.
Journal ArticleDOI
Vascular biomarkers and digital ulcerations in systemic sclerosis: results from a randomized controlled trial of oral treprostinil (DISTOL-1).
Christopher A. Mecoli,Jamie Perin,Jennifer E. Van Eyk,Jennifer E. Van Eyk,Jie Zhu,Qin Fu,Qin Fu,Andrew G. Allmon,Youlan Rao,Scott L. Zeger,Fredrick M. Wigley,Laura K. Hummers,Ami A. Shah +12 more
TL;DR: The lack of strong response to any of the vascular, angiogenic, or inflammatory markers suggest that these pathways are not primary drivers in the development of DU clinical outcomes in a SSc population with prevalent DU.
Journal ArticleDOI
Report from the Wellcome Trust/EBA “Perspectives in Clinical Proteomics” retreat--a strategy to implement next-generation proteomic analyses to the clinic for patient benefit: pathway to translation.
TL;DR: This viewpoint presents views derived from forums, proposing a pathway for the development of next‐generation proteomic analyses in the clinical setting from selection of candidates through to their validation and ultimate demonstration of utility through health technology assessments.